RT Journal Article
T1 Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.
A1 Prat, Aleix
A1 Galván, Patricia
A1 Jimenez, Begoña
A1 Buckingham, Wesley
A1 Jeiranian, H Arthur
A1 Schaper, Carl
A1 Vidal, Maria
A1 Álvarez, Martina
A1 Díaz, Sherley
A1 Ellis, Catherine
A1 Nuciforo, Paolo
A1 Ferree, Sean
A1 Ribelles, Nuria
A1 Adamo, Barbara
A1 Ramón Y Cajal, Santiago
A1 Peg, Vicente
A1 Alba, Emilio
AB Most hormone receptor (HR)(+)/HER2(-) breast cancer patients respond unfavorably to neoadjuvant chemotherapy (NAC); however, genomic tests may identify those patients who are likely to benefit. Using the Prosigna assay, we first evaluated the technical performance of core needle biopsy (CNB) tissues. We then determined whether Prosigna risk of relapse (ROR) score and intrinsic subtype predicted response to NAC in HR(+)/HER2(-) patients using CNB samples. Using the NanoString's nCounter Dx analysis system and a development tissue sample set, we established tissue requirements and assay output variance. We then evaluated the concordance in subtype and correlation in ROR between CNBs and corresponding surgical resection specimens (SRS) in a second independent sample set. Finally, we analyzed 180 independent CNB samples from HR(+)/HER2(-) patients who were treated with NAC and correlated ROR and intrinsic subtype with pathologic response. Intra- and interbiopsy variabilities were 2.2 and 6.8 ROR units, respectively. Subtype concordance within multiple CNBs was high for the 4- and 3-subtype classifications (k = 0.885 and 0.889, respectively). Correlation in Prosigna ROR score observed between paired CNBs and SRS was high (r ≥ 0.90), and subtype concordance was also high for the 4- and 3-subtype classifications (kappa = 0.81 and 0.91, respectively). Prosigna results obtained from the HR(+)/HER2(-) patient samples showed that both ROR (P = 0.047) and intrinsic subtype (OR LumA vs. non-LumA = 0.341, P = 0.037) were significant predictors of response to NAC. Prosigna ROR and intrinsic subtype are readily obtained from CNB samples in normal practice and reliably predict response to NAC in HR(+)/HER2(-) patients.
YR 2015
FD 2015-07-07
LK http://hdl.handle.net/10668/9950
UL http://hdl.handle.net/10668/9950
LA en
DS RISalud
RD Apr 8, 2025